From 2016 to 2022, the rate of maternal syphilis in the US tripled.
A study at a sexual health clinic finds that significant declines in chlamydia and syphilis were sustained nearly 2 years after doxy-PEP was introduced.
Relative to unexposed children, those with congenital syphilis were at a 6-fold increased risk for first hospitalization, and those exposed to maternal syphilis were at nearly twice the risk.
A study of 40 female sex workers reveals that a single daily dose of doxycycline is associated with significantly reduced STIs, primarily syphilis.
The leaders asked lawmakers for oversight hearings and to restore funding for critical public health programs.
The at-home test can detect chlamydia, gonorrhea, and trichomoniasis and deliver results within 30 minutes.
Researchers found that roughly 30% of chlamydia and gonorrhea patients did not receive treatment, while only 14% and 39% received recommended antibiotics.
Recurrence was cut in half when male partners of women who had bacterial vaginosis received a week of oral and topical antibiotics.
Researchers find a marked increase in tetracycline-resistant gonorrhea and increased colonization with tetracycline-resistant Staphylococcus aureus following the rollout of doxyPEP.
Among patients prescribed doxycycline post-exposure prophylaxis, cases of syphilis, chlamydia, and gonorrhea fell by 86.4%. 89.7%, and 54.7%, respectively.